Cargando…

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis

OBJECTIVE: The present study was undertaken to conduct a phase IV, open‐label, prospective study to characterize the long‐term safety of rituximab in a 4‐year observational registry of adult patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) within the US. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merkel, Peter A., Niles, John L., Mertz, Lester E., Lehane, Patricia B., Pordeli, Pooneh, Erblang, Félix, Allen, Nancy, Block, Joel A., Cartin‐Ceba, Rodrigo, Koening, Curry, Langford, Carol, Monach, Paul, Moreland, Larry W., Nachman, Patrick, Wallace, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Vasculitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457173/ https://www.ncbi.nlm.nih.gov/pubmed/32475029 http://dx.doi.org/10.1002/acr.24332

Ejemplares similares

Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021)

Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis
por: Samson, Maxime, et al.
Publicado: (2023)

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
por: Teixeira, Vítor, et al.
Publicado: (2019)

Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis
por: Jamois, Candice, et al.
Publicado: (2022)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Schirmer, Jan Henrik, et al.
Publicado: (2023)

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
por: Bettiol, Alessandra, et al.
Publicado: (2021)

Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
por: Melega, Simone, et al.
Publicado: (2022)

Proteinase 3 promotes formation of multinucleated giant cells and granuloma-like structures in patients with granulomatosis with polyangiitis
por: Henderson, Scott R, et al.
Publicado: (2023)

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry
por: Puéchal, Xavier, et al.
Publicado: (2022)

Eosinophilic granulomatosis polyangiitis (EGPA) complicated with periaortitis, precipitating role of dupilumab? A case report a review of the literature
por: Kai, Martine, et al.
Publicado: (2023)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis
por: Rhee, Rennie L., et al.
Publicado: (2018)

Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab
por: Geetha, Duvuru, et al.
Publicado: (2014)

Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Shah, Shivani, et al.
Publicado: (2015)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
por: Sanchez-Alamo, Beatriz, et al.
Publicado: (2023)

Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
por: Dejaco, Christian, et al.
Publicado: (2015)

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America
por: Doubelt, Irena, et al.
Publicado: (2021)

Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis
por: Doubelt, Irena, et al.
Publicado: (2022)

Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis
por: Harigai, Masayoshi, et al.
Publicado: (2019)

Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis
por: Endo, Yushiro, et al.
Publicado: (2018)

Eosinophilic Granulomatosis with Polyangiitis and Diffuse Gastrointestinal Involvement
por: Franco, Diana L., et al.
Publicado: (2014)

Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan
por: Sugiyama, Koichi, et al.
Publicado: (2012)

Role of bronchoscopy for respiratory involvement in granulomatosis with polyangiitis and microscopic polyangiitis
por: Villeneuve, Thomas, et al.
Publicado: (2023)

Successful rituximab treatment of granulomatosis with polyangiitis with cranial neuropathies
por: Nakazawa, Maho, et al.
Publicado: (2018)

Activation of natural killer cells by rituximab in granulomatosis with polyangiitis
por: Urlaub, Doris, et al.
Publicado: (2019)

A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis
por: Quan, Michele V., et al.
Publicado: (2018)

Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis
por: Owczarczyk, Kasia, et al.
Publicado: (2020)

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2017)

Eosinophilic granulomatosis with polyangiitis with severe pulmonary hemorrhage treated with rituximab
por: Baikunje, S., et al.
Publicado: (2016)

Successful Treatment with Rituximab for Granulomatosis with Polyangiitis and Multiple Cranial Neuropathies
por: Horiuchi, Kazuhiro, et al.
Publicado: (2020)

Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis
por: Puéchal, Xavier, et al.
Publicado: (2022)

Rituximab-Induced Colitis and Esophagitis in a Patient With Granulomatosis With Polyangiitis
por: Boateng, William K, et al.
Publicado: (2023)

Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis
por: Iudici, Michele, et al.
Publicado: (2016)

The Efficacy of Mycophenolate Mofetil in Remission Maintenance Therapy for Microscopic Polyangiitis and Granulomatosis with Polyangiitis
por: Pyo, Jung Yoon, et al.
Publicado: (2021)

Serum adipokine profiles in patients with microscopic polyangiitis and granulomatosis with polyangiitis: An exploratory analysis
por: Ahn, Sung Soo, et al.
Publicado: (2021)

Penile granulomatosis with polyangiitis
por: Amico, Séverine, et al.
Publicado: (2019)

Eosinophilic Granulomatosis with Polyangiitis
por: Shukla, Ratnakar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pfmui886clv39k5290jqom6bao